About US
Contact us
-
Vertex strikes deal for Orkambi and Symkevi in Scotland, ramping up pressure on holdout EnglandVertex Pharmaceuticals and English health officials have for years been unable to strike a deal for cystic fibrosis drug access, but Vertex's new deal with neighbor Scotland may pile on the pressure.2019/9/11
-
Purdue inks multibillion-dollar opioid deal with thousands of local governments, more than 20 states: reportsPurdue Pharma has entered the first major opioid settlement. The company, whose OxyContin played a role in the opioid epidemic, plans to file for bankruptcy imminently and restructure under an agreem2019/9/11
-
Xeris scores first FDA nod with shelf-stable glucagon injector, syringeDiabetes drugmaker Xeris Pharmaceuticals made a $75 million bet last summer when it went public to back an FDA submission for its shelf-stable glucagon injector pen. Now, more than a year later, Xeri2019/9/10
-
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera dataThe multiple sclerosis field has grown increasingly competitive in recent years, but now Biogen is touting data the drugmaker believes will give its established Tecfidera an edge new rivals can’t mat2019/9/10
-
Acadia calls early halt to Nuplazid psychosis trial after promising interim resultsAcadia was stung hard after its schizophrenia hopes for flagship Nuplazid fell flat back in late July. On the heels of that failure, Acadia is calling off a trial in dementia-related psychosis (DRP)2019/9/9
-
WCLC: Roche's Tecentriq comes up short in squamous lung cancer, leaving Merck's Keytruda 'unchallenged'Roche has been hoping its Tecentriq could put up the kind of life-lengthening numbers in squamous non-small cell lung cancer (NSCLC) that could help it compete with Merck’s Keytruda—but no dice. The2019/9/9
-
Pharma's worst nightmare? Leaked Democrat pricing plan calls for negotiations, price index, fines and morePharma watchers have been awaiting House Speaker Nancy Pelosi’s drug pricing plan, and on Monday the industry got a peek at whatDemocrats are discussing to lower drug prices. The upshot? If the House2019/9/6
-
J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in?Johnson & Johnson is attempting to change the antidepression market with its ketamine-derivative Spravato despite strict dosing requirements and a steep list price. New data in treating high-risk2019/9/6
-
ICER's blasted pharma pricing for years, but now drugmakers are 'rolling up their sleeves' to cooperateSanofi and Regeneron's next-gencholesterol drug Praluent never lived up to early expectations, and its price tag was at least partly to blame. The cost petrified payers. Even before it—and its fellow2019/9/5
-
WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival winMerck’s Keytruda-chemo combo has a history of silencing its critics when it comes to its effectiveness in previously untreated non-small cell lung cancer patients. And it may have just done it again.2019/9/5